Please provide your email address to receive an email when new articles are posted on . The PFS benefit from adding a vaccine to pembrolizumab narrowly missed the statistical significance threshold.
DURHAM, N.C. and BEIJING, Dec. 12, 2021 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a multi-national company developing innovative therapies for ...
- Arcus will host a conference call today, Wednesday, June 23, 2021 at 2:00 p.m. Pacific Time/5:00 p.m. Eastern Time to provide an update on its ongoing domvanalimab program HAYWARD, Calif.--(BUSINESS ...
The presentation of the complete data from the NRG-GY004 trial comes just months after AstraZeneca and Merck announced in a press release that the combination failed to meet its primary endpoint of ...
In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate (4 of 4 patients) and a 100% disease control rate, ...
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Initial results from the TROPION-Lung02 phase 1b trial showed that datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab with or without ...
SOUTH SAN FRANCISCO, Calif., May 5, 2011 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the publication of new nonclinical data by a leading academic group on the ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nimbus Therapeutics, a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, today announced the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results